News & Media

202420232022202120202019201820172016201520142013
Press release 2024/04/30 Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2024

”Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened...

Read more
Press release 2024/04/29
Medivir brings the Q1 webcast forward to 10 a.m. on April 30

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/04/29
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/04/25
FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/04/23
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/04/15
Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/04/09
Medivir to present at Investing in Oncology Forum on April 10

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/04/04 Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...

Read more
Press release 2024/04/04 Regulatory
Medivir 2023 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the...

Read more
Press release 2024/03/06
Medivir to present at Swiss Nordic Bio in Zürich on March 7

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/03/04
Medivir to present at the Life Science Day in Gothenburg on March 6

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/02/26
Change in Medivir's nomination committee before the 2024 AGM

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that that the nomination committee before the annual general meeting in...

Read more